Bohlen H, Thielemanns K, Tesch H, Engert A, Wolf H J, van Camp B, Urbain J, Diehl V
Klinik I für Innere Medizin, Universität zu Köln, Germany.
Cytokines Mol Ther. 1996 Dec;2(4):231-8.
Three strategies were used to evaluate 38C13 B-cell lymphoma-specific idiotype immunization to protect against subsequent lymphoma challenge in C3H/He mice. It was observed that tumor-specific immunity could be induced by immunization with (i) KLH-conjugated 38C13 B-cell lymphoma idiotype in complete Freund's adjuvants (survival rate 80%), (ii) dendritic cells pulsed in vitro with native idiotype protein (survival rate 80%), and (iii) bispecific antibodies composed of B-lymphoma-related idiotype and an MHC class II binding moiety (survival rate 40%). Presentation of idiotype determinants by dendritic cells or bispecific antibody resulted in lymphoma-specific immunity and obviated the requirement for carrier protein or adjuvant. Moreover, primed dendritic cells induced predominant development of a tumor-specific T-cell response. Each of these immunization strategies resulted in long-term survival without the emergence of idiotype variants or the induction of tumor dormancy.
采用三种策略评估38C13 B细胞淋巴瘤特异性独特型免疫对C3H/He小鼠后续淋巴瘤攻击的保护作用。结果发现，通过以下方式免疫可诱导肿瘤特异性免疫：（i）在完全弗氏佐剂中用钥孔血蓝蛋白（KLH）偶联的38C13 B细胞淋巴瘤独特型（存活率80%）；（ii）用天然独特型蛋白体外脉冲处理的树突状细胞（存活率80%）；（iii）由B淋巴瘤相关独特型和MHC II类结合部分组成的双特异性抗体（存活率40%）。树突状细胞或双特异性抗体呈递独特型决定簇可产生淋巴瘤特异性免疫，无需载体蛋白或佐剂。此外，经致敏的树突状细胞诱导肿瘤特异性T细胞反应占主导地位。这些免疫策略中的每一种都能使小鼠长期存活，且不会出现独特型变体或诱导肿瘤休眠。
